Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2460/javma.20.04.0176 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Validation of mortality risk scores after esophagectomy.
J Cancer Res Clin Oncol
January 2025
Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Purpose: Oncological esophagectomy is the mainstay in esophageal cancer treatment, but perioperative mortality remains a significant concern. Various scoring systems exist to identify patients at high risk for postoperative complications and death. In the following, we aim to evaluate and compare these different scoring systems.
View Article and Find Full Text PDFAssociation of BCHE gene SNP rs1803274 (K-variant) and rs3495 with obesity in Pakistani population group.
Int J Obes (Lond)
January 2025
Department of Biosciences, COMSATS University Islamabad, Park Road Tarlai, Islamabad, 45550, Pakistan.
Background: Obesity plays a crucial role in the development of metabolic disorders including diabetes, coronary and renal diseases. There are several factors involved in the pathology of obesity, including chronic inflammation and exposure to environmental contaminants. Recently, the cholinergic co-hydrolyzing enzyme BChE has been associated with clinical conditions such as diabetes and obesity.
View Article and Find Full Text PDFLenvatinib versus sorafenib as second-line therapy following progression on atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan.
J Cancer Res Clin Oncol
January 2025
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Purpose: Atezolizumab-bevacizumab (AB) is the established first-line systemic therapy for patients with unresectable hepatocellular carcinoma (uHCC). However, the optimal second-line treatment for patients unresponsive to AB remains undefined.
Patients And Methods: This multicenter, retrospective study included patients with uHCC who underwent second-line treatment with lenvatinib (LEN) or sorafenib (SOR) after AB failure at two academic centers between June 2018 and November 2023.
Muscle pseudohypertrophy as the presenting manifestation of autoimmune hypothyroidism: Hoffmann's syndrome.
BMJ Case Rep
January 2025
Internal Medicine, RG Kar Medical College and Hospital, Kolkata, West Bengal, India.
Hoffmann syndrome, a rare manifestation of hypothyroid myopathy in adults, is characterised by muscle weakness, stiffness and pseudohypertrophy. Here, we report the case of a middle-aged man who presented with progressive weakness in proximal muscles (in the form of difficulty in climbing stairs, rising from a seated position, combing hair and lifting objects) and leg swelling for 6 months. Physical examination revealed pseudohypertrophy of calf muscles with pronounced symmetric weakness in proximal upper and lower limbs.
View Article and Find Full Text PDFAims: The current American Joint Committee on Cancer (AJCC) staging manual and the College of American Pathologists (CAP) colorectal carcinoma (CRC) protocol specify use of a four-tiered grading system (i.e. grades 1-4; well-differentiated-undifferentiated) for CRC, based on percentage of gland formation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!